HBC Hofseth Biocare

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago

According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®.

ProGo® Bioactive Peptides optimize the metabolism of glucose and fat to improve energy levels and weight profile. Their novel mode of action extends the healthspan of all ages to allow a more active lifestyle for longer. As a result, ProGo® is gaining increasing attention for consumer health and medical nutrition applications.

For further information, please contact:

James Berger, Chief Commercial Officer of Hofseth BioCare ASA

Phone:

E-mail:

About Hofseth BioCare ASA:

Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by taking fresh filleted salmon and converting it from a waste product into ingredients to improve human and pet health. These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid fractions contained in fish, and CalGo® / NT-II(TM) salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health.

HBC places scientific evidence at the forefront which has led to important academic partnerships and the identification of unique health benefits. This includes the demonstration of improved iron metabolism by boosting the body's ability to take up and use iron resulting in increased energy and vitality with ProGo® as well as the activation of the GLP-1 receptor with fat reduction in overweight adults. OmeGo® has shown important immune health benefits including recovery from viral infection and improved respiratory health and sleep in adults troubled by particulate matter pollution. Finally, CalGo® has shown both bone and joint health benefits to support healthy ageing and active lifestyles. This work has also resulted in the granting of a number of patents protecting these discoveries. It has also led to the discovery of potential therapeutics and HBC has spun out a biotech-focused company, HBC Immunology (HBCI). HBCI has raised external finance, and the lead program is in prostate cancer followed by ovarian cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for asthma.



EN
16/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for H...

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®. ProGo® Bioactive Peptides optimize the metabolis...

 PRESS RELEASE

Hofseth Biocare ASA: Annual General Meeting completed

Hofseth Biocare ASA: Annual General Meeting completed Hofseth BioCare ASA held its Annual General Meeting on 23 May 2025. All proposals were resolved as presented in the notice issued on 2 May 2025. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: E-mail: About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by takin...

 PRESS RELEASE

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting a 15% increase from Q1 2024 (NOK 52.1 million), driven by continued growth in higher-margin human and pet health segments, despite early-quarter production constraints and ongoing pressure in the commodity oil market. Cost of goods sold (CoGS) amounted to NOK 37.5 million, up from NOK 27.3 million in Q1 2024. Operating expenses total...

 PRESS RELEASE

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SP...

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US Nestlé-owned Garden of Life has launched OmeGo® Full Spectrum Omegas on Amazon in the US. Branded as “Norwegian Salmon Oil”, it retains the complete balance and nutritional profile of fresh Atlantic salmon in a softgel format. Joining Garden of Life’s portfolio of health supplements available online, Norwegian Salmon Oil containing OmeGo® is gently liberated from fresh, sashimi-grade salmon and provides whole-fish health benefits from its full spectrum of omegas. It differentiates from a competiti...

 PRESS RELEASE

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSEC...

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS Reference is made to the stock exchange notice published by Hofseth BioCare ASA (the "Company") on 10 March 2025 regarding a contemplated bond issuance. The Company is pleased to announce that it has now successfully placed CHF-denominated unsecured bonds for a total amount of approximately CHF 3.5 million (the "Bonds"). The Bonds were subscribed for by investors in Switzerland and Liechtenstein. Settlement of the Bonds issue is expected to occur simultaneously as the issue date, which is expected to be on 5 M...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch